Clinical Trial Launch, Acquisition, Conference Schedule, Reimbursement Rates Impact, and Product Approval - Research Report on

 Clinical Trial Launch, Acquisition, Conference Schedule, Reimbursement Rates
  Impact, and Product Approval - Research Report on NewLink, Addus HomeCare,
                     Wright Medical, Alliance, and USANA

PR Newswire

NEW YORK, January 6, 2014

NEW YORK, January 6, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting NewLink
Genetics Corporation (NASDAQ: NLNK), Addus HomeCare Corporation (NASDAQ:
ADUS), Wright Medical Group, Inc. (NASDAQ: WMGI), Alliance HealthCare
Services, Inc. (NASDAQ: AIQ), and USANA Health Sciences, Inc. (NYSE: USNA).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

NewLink Genetics Corporation Research Report

On December 19, 2013, NewLink Genetics Corporation (NewLink) announced that it
had launched a first in human Phase 1 clinical trial of HyperAcute Renal
immunotherapy in patients with metastatic renal cell cancer. "HyperAcute Renal
represents our sixth HyperAcute immunotherapy to advance into clinic," said
Dr. Charles Link, Chairman and CEO of NewLink. "As with pancreatic cancer and
algenpantucel-L, we believe renal cell cancer may also be particularly well
suited to HyperAcute Renal immunotherapy. We continue to develop new
HyperAcute immunotherapies as we approach the initial interim analysis of our
pivotal IMPRESS trial for algenpantucel-L, our lead HyperAcute immunotherapy
for patients with resected pancreatic cancer." The Company notified that the
Phase 1 dose-escalation study aims primarily to determine the safety of
HyperAcute Renal immunotherapy cells administered by intradermal injection in
up to 20 patients with recurrent or refractory, metastatic clear-cell renal
cancer. The Full Research Report on NewLink Genetics Corporation - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/c592_NLNK

Addus HomeCare Corporation Research Report

On December 6, 2013, Addus HomeCare Corporation (Addus HomeCare) announced
that it has closed on its acquisition of the previously announced purchase of
substantially all of the assets of Coordinated Home Health Care, LLC
(Coordinated Home Health Care) and certain of its subsidiaries, effective as
of December 1, 2013. Addus HomeCare notified that the acquisition includes 15
offices in southern New Mexico and further expands the Company's presence in
the state. "We are pleased to complete the purchase of Coordinated Home Health
as it substantially expands or footprint in New Mexico, a state which is on
the forefront of transitioning its Medicaid long term care programs to managed
care," said Mark Heaney, President and CEO of Addus HomeCare. The Full
Research Report on Addus Homecare Corporation - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/2b69_ADUS

Wright Medical Group, Inc. Research Report

On December 18, 2013, Wright Medical Group, Inc. (Wright Medical) announced
its participation at the 32^nd Annual J.P. Morgan Healthcare Conference on
January 13, 2014 at the Westin St. Francis Hotel in San Francisco, California.
The Company informed that it's President and CEO, Robert Palmisano, is
scheduled to make the presentation at 2:30 p.m. PT on the aforesaid date.
Wright Medical stated that the live audio webcast of the conference
presentation and replay of the same will be accessible through its Investor
Relations website. The Full Research Report on Wright Medical Group, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1782_WMGI

Alliance HealthCare Services, Inc. Research Report

On December 12, 2013, Alliance HealthCare Services, Inc. (Alliance) announced
additional information regarding the potential impact of the final 2014
Medicare reimbursement rates, which were issued on November 27, 2013 by the
Centers for Medicare and Medicaid Studies (CMS). The Company notified that the
total impact to Alliance is a predicted reduction of c.$2.8 million in
Medicare reimbursement, based on 2013 estimated volume data. "We are pleased
to receive the final rule, which now allows us to more accurately plan for the
impact in 2014. While slightly more than our initial impact expectations of $2
million, this change in reimbursement represents approximately 2% of our full
year 2013 Adjusted EBITDA guidance range. This is a manageable amount and will
not hinder our ability to do business or our focus on expanding our
relationships and providing added value to our hospital partners," said Howard
Aihara, Executive Vice President and CFO of Alliance. The Full Research Report
on Alliance HealthCare Services, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/7913_AIQ

USANA Health Sciences, Inc. Research Report

On December 5, 2013, USANA Health Sciences, Inc. (USANA) announced that one of
its top-rated supplements, newly upgraded dairy- and sugar-free USANA
Probiotic, has been evaluated and approved by ConsumerLab.com LLC
(ConsumerLab.com), a company that independently tests health products for
purity, disintegration and strength. According to the Company, ConsumerLab.com
also approved USANA Essentials, Body Rox, Usanimals, and CoQuinone 30
supplements. "It's an honor to receive product certification by a reputable
third-party organization such as ConsumerLab.com," said Dan Macuga, Chief
Communications Officer of USANA. "It demonstrates our resilient commitment to
producing effective and reliable products for consumers." The Full Research
Report on USANA Health Sciences, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/ee40_USNA

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.